AWP OVERSTATES ACTUAL PHARMACY INVOICE COST FOR BRAND NAME DRUGS BY AVERAGE OF 18.3% NATIONWIDE, HHS IG CONCLUDES; GENERIC AWP OVERSTATES COST BY 42.5%
Average wholesale price overstates actual pharmacy acquisition costs for brand name drugs by 18.3%, the HHS Inspector General's Office has concluded based on an audit of state Medicaid payment rates.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth